Moderna's hMPV project a chance to prove its staying power

Following the successful development and rapid roll-out of its COVID-19 vaccine, Moderna (Nasdaq: MRNA) has wasted no time in seeking to prove that it is not a one-trick pony.

The US mRNA company’s pipeline of vaccines and therapeutics is full of wider potential, targeting everything from flu, respiratory syncytial virus (RSV), cytomegalovirus, HIV, cancer, lyme diseases, Zi ka and more.

Another disease that Moderna is committed to tackling is hMPV, formally human metapneumovirus, which can cause severe infections and is particularly dangerous for young children, older adults, and people with weakened immune systems. It is a relative to RSV.